Emery Pharma Co-Sponsors PDA West Coast Event on CMC Strategy for Parenteral and Novel Drug Modalities
Emery Pharma announced its role as co-sponsor and host of the Parenteral Drug Association (PDA) – West Coast Chapter upcoming industry program focused on CMC considerations for parenteral drug products…
Emery Pharma and Fortrea Launch Podcast on Restoring Rifampin for Safer DDI Studies
Alameda, CA | July 28, 2025 – Emery Pharma, a leading GLP/GMP-certified analytical laboratory, is proud to announce the release of a special podcast episode featuring Dr. Marcus Stavchansky, Global…
Nitrosamine Risk Assessment: Are You Prepared for the August 1, 2025 Deadline?
The FDA’s deadline is fast approaching. Let us help you stay compliant. Whether you’re a formulation scientist, process chemist, analytical chemist, regulatory affairs specialist, or drug delivery expert, understanding nitrosamines—and…
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies Source: GlobeNewswire DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the…
Emery Pharma and Rayner Announce Publication of a Successful Validation of Bioanalytical Method for Quantifying Ketorolac in Human Vitreous and Aqueous Humor Using a Surrogate Matrix of Human Plasma, in Accordance with ICH M10 Guidelines
Emery Pharma, a leading contract research organization specializing in bioanalytical method development and validation, has partnered with Rayner to develop and validate a novel bioanalytical method for measuring ketorolac concentrations…
Emery Pharma Sponsors PDA Event on Artificial Intelligence in Biopharmaceutical Development and Manufacturing
Alameda, CA – Emery Pharma, a leader in analytical testing and research services, is proud to announce its sponsorship of the upcoming Parenteral Drug Association (PDA) event, Artificial Intelligence in…
Centivax and Emery Pharma Partner to Accelerate Universal Vaccine Clinical Readiness
Centivax, a biotechnology company that develops broad-spectrum vaccines to combat rapidly evolving pathogens, has announced a strategic collaboration with Emery Pharma, a leading contract research organization specializing in GLP/cGMP compliant…
Emery Pharma and AbVacc Announce Strategic Collaboration to Develop Super Fast-Acting Intranasal Naloxone
San Francisco, CA, and Rockville, MD –Emery Pharma, a leading pharmaceutical research organization in the San Francisco Bay Area, and AbVacc, a renowned biotechnology company headquartered in Rockville, Maryland, are…
Emery Pharma Attending 2025 J.P. Morgan 43rd Annual Healthcare Conference
ALAMEDA, CA – Emery Pharma has announced that CEO, Ron Najafi, Ph.D., and the Business Development team will be available during the JP Morgan Annual Healthcare Conference, held on January 13…
Emery Pharma to Attend the Annual ACT Meeting in Austin Texas
Emery Pharma, a leading contract research organization (CRO) based in Alameda, CA, specializing in pharmaceutical and biotechnology solutions, is pleased to announce its attendance at the upcoming American College of…